Search

Your search keyword '"Trusolino, Livio"' showing total 772 results
Start Over Author "Trusolino, Livio"
772 results on '"Trusolino, Livio"'

202. Changes in integrin and E-cadherin expression in neoplastic versus normal thyroid tissue

Author

Serini, Guido, Trusolino, Livio, Saggiorato, Enrico, Cremona, Ottavio, De Rossi, Marco, Angeli, Alberto, Orlandi, Fabio, and Marchisio, Pier Carlo

Subjects
Cell adhesion -- Molecular aspects, Cancer -- Molecular aspects, Endocrine gland tumors -- Physiological aspects, Health
Abstract

Background: The functional organization of polarized epithelia depends mostly on adhesion molecules belonging to the integrin and cadherin families. These molecules either recognize basement membrane components, such as laminins, or form intercellular junctions via homotypic interactions. Such tissue organization is often disrupted upon neoplastic transformation, and the resulting loss of functional polarization and cell cohesion might be a prerequisite for the invasive and metastatic behavior of carcinomas. Purpose: We studied modifications of thyrod adhesive mechanisms at various stages of neoplastic progression in terms of adhesion molecule expression, topography, and functional regulation by tyrosine kinases. Starting from this working hypothesis, we sought to identify one or more biological markers that would be suggestive of malignant transformation and poorer prognosis and that could be developed as a reliable indicator(s) in early diagnostic steps. Methods: The study was carried out on both surgical samples and the corresponding fine-needle aspiration biopsy smears (numbers of specimens collected: 19 adenomas, seven follicular carcinomas, 13 papillary carcinomas, and 39 normal tissues). Immunohistochemistry of tissue sections and smears and immunoprecipitation and western blot analysis of protein extracts were done with a battery of monoclonal and polyclonal antibodies. Northern blotting was performed on RNA extracts from frozen tissue samples and use of an integrin subunit [[beta].sub.4] complementary DNA probe. Results: Our findings can be summarized as follows: 1) In normal thyroid cells, the cooperative role of integrin [[alpha].sub.6][[beta].sub.4] and laminin 5/kalinin in hemidesmosome-mediated adhesion is missing, and recognition of the basal lamina occurs via integrin [[alpha].sub.4][[beta].sub.1] and laminin 1 and/or 2 (this pattern being maintained in adenomas but altered in carcinomas regardless of their histotype or differentiation grade); 2) only in carcinomas with clinical and/or histologic aggressiveness do neoexpression of integrin subunit [[beta].sub.4] and loss of laminin 2/merosin occur, indicating de novo assembly of integrin [[alpha].sub.6][[beta].sub.4]; 3) pericellular redistribution and cytoskeletal disconnection of the E-cadherin-catenin complex occur; and 4) basal E-cadherin tyrosine phosphorylation decreases in carcinomas as compared with that in normal and adenomatous tissues. Conclusions: The malignant progression of thyroid tumors involves marked rearrangements of cell-basement membrane and cell-cell adhesion molecules and changes in their cytoskeleton linkage. These rearrangements are also easily and reproducibly detected on fine-needle aspiration biopsy smears. Implications: Immunodetection of adhesion molecules in sections and/or fine-needle smears may complement the toolbox of thyroid surgical pathologists; it may expand the possibilities of achieving a correct early diagnosis of thyroid tumors and of gaining some prognostic information on thyroid tumors. [J Natl Cancer Inst 1996; 88:442-9]

Published
1996

203. Systems analysis of protein signatures predicting cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild‐type patient‐derived xenograft models of metastatic colorectal cancer.

Author

Lindner, Andreas U., Carberry, Steven, Monsefi, Naser, Barat, Ana, Salvucci, Manuela, O'Byrne, Robert, Zanella, Eugenia R., Cremona, Mattia, Hennessy, Bryan T., Bertotti, Andrea, Trusolino, Livio, and Prehn, Jochen H. M.

Subjects
PROTEIN analysis, COLORECTAL cancer, EPIDERMAL growth factor receptors, METASTASIS, SYSTEM analysis
Abstract

Antibodies targeting the human epidermal growth factor receptor (EGFR) are used for the treatment of RAS wild‐type metastatic colorectal cancer. A significant proportion of patients remains unresponsive to this therapy. Here, we performed a reverse‐phase protein array‐based (phospho)protein analysis of 63 KRAS, NRAS, BRAF and PIK3CA wild‐type metastatic CRC tumours. Responses of tumours to anti‐EGFR therapy with cetuximab were recorded in patient‐derived xenograft (PDX) models. Unsupervised hierarchical clustering of pretreatment tumour tissue identified three clusters, of which Cluster C3 was exclusively composed of responders. Clusters C1 and C2 exhibited mixed responses. None of the three protein clusters exhibited a significant correlation with transcriptome‐based subtypes. Analysis of protein signatures across all PDXs identified 14 markers that discriminated cetuximab‐sensitive and cetuximab‐resistant tumours: PDK1 (S241), caspase‐8, Shc (Y317), Stat3 (Y705), p27, GSK‐3β (S9), HER3, PKC‐α (S657), EGFR (Y1068), Akt (S473), S6 ribosomal protein (S240/244), HER3 (Y1289), NF‐κB‐p65 (S536) and Gab‐1 (Y627). Least absolute shrinkage and selection operator and binominal logistic regression analysis delivered refined protein signatures for predicting response to cetuximab. (Phospo‐)protein analysis of matched pretreated and posttreated models furthermore showed significant reduction of Gab‐1 (Y627) and GSK‐3β (S9) exclusively in responding models, suggesting novel targets for treatment. What's new? Therapies that neutralize epidermal growth factor receptor (EGFR) activity have greatly improved survival in metastatic colorectal cancer (mCRC) patients. Still, many patients will fail to respond to therapy, despite having wild‐type KRAS, which generally predicts anti‐EGFR therapeutic efficacy. Here, statistical analysis of reverse phase protein array data from KRAS, BRAF, NRAS, and PI3KCA wild‐type mCRC patient‐derived xenograft mouse models shows that response to the anti‐EGFR therapy cetuximab is reliably predicted by a 14 (phospho)protein marker signature. The findings further suggest that GSK‐3β, dysregulation of which is associated with cancer, is a promising target for co‐treatment with cetuximab. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

204. Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells

Author

Sogari, Alberto, Rovera, Emanuele, Grasso, Gaia, Mariella, Elisa, Reilly, Nicole Megan, Lamba, Simona, Mauri, Gianluca, Durinikova, Erika, Vitiello, Pietro Paolo, Lorenzato, Annalisa, Avolio, Marco, Piumatti, Eleonora, Bonoldi, Emanuela, Aquilano, Maria Costanza, Arena, Sabrina, Sartore-Bianchi, Andrea, Siena, Salvatore, Trusolino, Livio, Donalisio, Manuela, Russo, Mariangela, Di Nicolantonio, Federica, Lembo, David, and Bardelli, Alberto

Abstract

The bacterial genotoxin colibactin promotes colorectal cancer (CRC) tumorigenesis, but systematic assessment of its impact on DNA repair is lacking, and its effect on response to DNA-damaging chemotherapeutics is unknown. We find that CRC cell lines display differential response to colibactin on the basis of homologous recombination (HR) proficiency. Sensitivity to colibactin is induced by inhibition of ATM, which regulates DNA double-strand break repair, and blunted by HR reconstitution. Conversely, CRC cells chronically infected with colibactin develop a tolerant phenotype characterized by restored HR activity. Notably, sensitivity to colibactin correlates with response to irinotecan active metabolite SN38, in both cell lines and patient-derived organoids. Moreover, CRC cells that acquire colibactin tolerance develop cross-resistance to SN38, and a trend toward poorer response to irinotecan is observed in a retrospective cohort of CRCs harboring colibactin genomic island. Our results shed insight into colibactin activity and provide translational evidence on its chemoresistance-promoting role in CRC.

Published
2024
Full Text
View/download PDF

205. Abstract 1821: Genome-wide genetic screens define the drug resistance landscape of BRAF mutant colon cancer

Author

Brammeld, Jonathan, primary, Ranzani, Marco, additional, Coker, Elizabeth A., additional, Price, Stacey, additional, Roumeliotis, Theodoros I., additional, Lupo, Barbara, additional, Petljak, Mi, additional, Williams, Steven P., additional, Iorio, Francesco, additional, Sassi, Francesco, additional, Aben, Nanne, additional, Yusa, Kosuke, additional, Trusolino, Livio, additional, Wessels, Lodewyk, additional, Adams, David J., additional, Garnett, Mathew, additional, Al-Lazikani, Bissan, additional, Choudhary, Jyoti S., additional, Bertotti, Andrea, additional, and McDermott, Ultan, additional

Published
2018
Full Text
View/download PDF

207. Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer

Author

Siravegna, Giulia, primary, Lazzari, Luca, additional, Crisafulli, Giovanni, additional, Sartore-Bianchi, Andrea, additional, Mussolin, Benedetta, additional, Cassingena, Andrea, additional, Martino, Cosimo, additional, Lanman, Richard B., additional, Nagy, Rebecca J., additional, Fairclough, Stephen, additional, Rospo, Giuseppe, additional, Corti, Giorgio, additional, Bartolini, Alice, additional, Arcella, Pamela, additional, Montone, Monica, additional, Lodi, Francesca, additional, Lorenzato, Annalisa, additional, Vanzati, Alice, additional, Valtorta, Emanuele, additional, Cappello, Giovanni, additional, Bertotti, Andrea, additional, Lonardi, Sara, additional, Zagonel, Vittorina, additional, Leone, Francesco, additional, Russo, Mariangela, additional, Balsamo, Antonella, additional, Truini, Mauro, additional, Di Nicolantonio, Federica, additional, Amatu, Alessio, additional, Bonazzina, Erica, additional, Ghezzi, Silvia, additional, Regge, Daniele, additional, Vanzulli, Angelo, additional, Trusolino, Livio, additional, Siena, Salvatore, additional, Marsoni, Silvia, additional, and Bardelli, Alberto, additional

Published
2018
Full Text
View/download PDF

208. Abstract 2848: Radiographic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer

Author

Siravegna, Giulia, primary, Lazzari, Luca, additional, Sartore-Bianchi, Andrea, additional, Crisafulli, Giovanni, additional, Mussolin, Benedetta, additional, Cassingena, Andrea, additional, Martino, Cosimo, additional, Lanman, Richard, additional, Nagy, Rebecca, additional, Corti, Giorgio, additional, Bartolini, Alice, additional, Arcella, Pamela, additional, Montone, Monica, additional, Lodi, Francesca, additional, Vanzati, Alice, additional, Valtorta, Emanuele, additional, Cappello, Giovanni, additional, Bertotti, Andrea, additional, Lonardi, Sara, additional, Zagonel, Vittorina, additional, Leone, Francesco, additional, Russo, Mariangela, additional, Balsamo, Antonella, additional, Truini, Mauro, additional, Nicolantonio, Federica Di, additional, Amatu, Alessio, additional, Bonazzina, Erica, additional, Ghezzi, Silvia, additional, Regge, Daniele, additional, Vanzulli, Angelo, additional, Trusolino, Livio, additional, Siena, Salvatore, additional, Marsoni, Silvia, additional, and Bardelli, Alberto, additional

Published
2018
Full Text
View/download PDF

210. Plasma HER2 (ERBB2) copy number to predict response to HER2-targeted therapy in metastatic colorectal cancer.

Author

Bardelli, Alberto, primary, Siravegna, Giulia, additional, Sartore-Bianchi, Andrea, additional, Nagy, Rebecca J, additional, Mussolin, Benedetta, additional, Cassingena, Andrea, additional, Martino, Cosimo, additional, Lonardi, Sara, additional, Zagonel, Vittorina, additional, Leone, Francesco, additional, Amatu, Alessio, additional, Trusolino, Livio, additional, Odegaard, Justin, additional, Lanman, Richard B., additional, Marsoni, Silvia, additional, and Siena, Salvatore, additional

Published
2018
Full Text
View/download PDF

212. A Molecularly Annotated Model of Patient-Derived Colon Cancer Stem–Like Cells to Assess Genetic and Nongenetic Mechanisms of Resistance to Anti-EGFR Therapy

Author

Luraghi, Paolo, primary, Bigatto, Viola, additional, Cipriano, Elia, additional, Reato, Gigliola, additional, Orzan, Francesca, additional, Sassi, Francesco, additional, De Bacco, Francesca, additional, Isella, Claudio, additional, Bellomo, Sara E., additional, Medico, Enzo, additional, Comoglio, Paolo M., additional, Bertotti, Andrea, additional, Trusolino, Livio, additional, and Boccaccio, Carla, additional

Published
2018
Full Text
View/download PDF

213. Clinicopathological characteristics and HER2 status in metastatic colorectal cancer patients: Results of a diagnostic model development study.

Author

Sartore-Bianchi, Andrea, primary, Amatu, Alessio, additional, Porcu, Luca, additional, Ghezzi, Silvia, additional, Lonardi, Sara, additional, Bergamo, Francesca, additional, Bonazzina, Erica Francesca, additional, Mauri, Gianluca, additional, Cremolini, Chiara, additional, Ciardiello, Fortunato, additional, Valtorta, Emanuele, additional, Truini, Mauro, additional, Martino, Cosimo, additional, Marsoni, Silvia, additional, Di Nicolantonio, Federica, additional, Siravegna, Giulia, additional, Bardelli, Alberto, additional, Trusolino, Livio, additional, Torri, Valter, additional, and Siena, Salvatore, additional

Published
2018
Full Text
View/download PDF

214. Abstract A087: Empowering precision medicine in metastatic colorectal cancer: preliminary results from the FUNNEL platform

Author

Martino, Cosimo, primary, Berrino, Enrico, additional, Dell'Aglio, Carmine, additional, Casorzo, Laura, additional, Panero, Mara, additional, Siena, Salvatore, additional, Sartore-Bianchi, Andrea, additional, Cassingena, Andrea, additional, Zagonel, Vittorina, additional, Lonardi, Sara, additional, Loupakis, Fotios, additional, Tonini, Giuseppe, additional, Racca, Patrizia, additional, Trusolino, Livio, additional, Bertotti, Andrea, additional, Depetris, Ilaria, additional, Balsamo, Antonella, additional, Sapino, Anna, additional, and Marsoni, Silvia, additional

Published
2018
Full Text
View/download PDF

215. Abstract B049: Characterizing and targeting RET fusions-positive metastatic colorectal cancer (mCRC)

Author

Morano, Federica, primary, Schrock, Alexa, additional, Lee, Jeeyun, additional, Nikolinakos, Petros, additional, Drilon, Alexander, additional, Christiansen, Jason, additional, Chiu, Vi, additional, Zaniboni, Alberto, additional, Rossini, Daniele, additional, Kim, Seung Tae, additional, Milione, Massimo, additional, Patel, Rupal, additional, Miller, Vincet, additional, Corallo, Salvatore, additional, Di Bartolomeo, Maria, additional, Ross, Jeffrey, additional, Bertotti, Andrea, additional, Bardelli, Alberto, additional, Di Nicolantonio, Federica, additional, Ali, Siraj, additional, Trusolino, Livio, additional, Falcone, Alfredo, additional, de Braud, Filippo, additional, Cremolini, Chiara, additional, and Pietrantonio, Filippo, additional

Published
2018
Full Text
View/download PDF

216. Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling

Author

Ponsioen, Bas, Post, Jasmin B., Buissant des Amorie, Julian R., Laskaris, Dimitrios, van Ineveld, Ravian L., Kersten, Simone, Bertotti, Andrea, Sassi, Francesco, Sipieter, François, Cappe, Benjamin, Mertens, Sander, Verlaan-Klink, Ingrid, Boj, Sylvia F., Vries, Rob G. J., Rehmann, Holger, Vandenabeele, Peter, Riquet, Franck B., Trusolino, Livio, Bos, Johannes L., and Snippert, Hugo J. G.

Abstract

Direct targeting of the downstream mitogen-activated protein kinase (MAPK) pathway to suppress extracellular-regulated kinase (ERK) activation in KRASand BRAFmutant colorectal cancer (CRC) has proven clinically unsuccessful, but promising results have been obtained with combination therapies including epidermal growth factor receptor (EGFR) inhibition. To elucidate the interplay between EGF signalling and ERK activation in tumours, we used patient-derived organoids (PDOs) from KRASand BRAFmutant CRCs. PDOs resemble in vivo tumours, model treatment response and are compatible with live-cell microscopy. We established real-time, quantitative drug response assessment in PDOs with single-cell resolution, using our improved fluorescence resonance energy transfer (FRET)-based ERK biosensor EKAREN5. We show that oncogene-driven signalling is strikingly limited without EGFR activity and insufficient to sustain full proliferative potential. In PDOs and in vivo, upstream EGFR activity rigorously amplifies signal transduction efficiency in KRAS or BRAF mutant MAPK pathways. Our data provide a mechanistic understanding of the effectivity of EGFR inhibitors within combination therapies against KRASand BRAFmutant CRC.

Published
2021
Full Text
View/download PDF

217. Interrogating open issues in cancer precision medicine with patient-derived xenografts

Author

Byrne, Annette T., Alférez, Denis G., Amant, Frédéric, Annibali, Daniela, Arribas, Joaquín, Biankin, Andrew V., Bruna, Alejandra, Budinská, Eva, Caldas, Carlos, Chang, David K., Clarke, Robert B., Clevers, Hans, Coukos, George, Dangles-Marie, Virginie, Gail Eckhardt, S., Gonzalez-Suarez, Eva, Hermans, Els, Hidalgo, Manuel, Jarzabek, Monika A., De Jong, Steven, Jonkers, Jos, Kemper, Kristel, Lanfrancone, Luisa, Mælandsmo, Gunhild Mari, Marangoni, Elisabetta, Marine, Jean Christophe, Medico, Enzo, Norum, Jens Henrik, Palmer, Héctor G., Peeper, Daniel S., Pelicci, Pier Giuseppe, Piris-Gimenez, Alejandro, Roman-Roman, Sergio, Rueda, Oscar M., Seoane, Joan, Serra, Violeta, Soucek, Laura, Vanhecke, Dominique, Villanueva, Alberto, Vinolo, Emilie, Bertotti, Andrea, Trusolino, Livio, Byrne, Annette T., Alférez, Denis G., Amant, Frédéric, Annibali, Daniela, Arribas, Joaquín, Biankin, Andrew V., Bruna, Alejandra, Budinská, Eva, Caldas, Carlos, Chang, David K., Clarke, Robert B., Clevers, Hans, Coukos, George, Dangles-Marie, Virginie, Gail Eckhardt, S., Gonzalez-Suarez, Eva, Hermans, Els, Hidalgo, Manuel, Jarzabek, Monika A., De Jong, Steven, Jonkers, Jos, Kemper, Kristel, Lanfrancone, Luisa, Mælandsmo, Gunhild Mari, Marangoni, Elisabetta, Marine, Jean Christophe, Medico, Enzo, Norum, Jens Henrik, Palmer, Héctor G., Peeper, Daniel S., Pelicci, Pier Giuseppe, Piris-Gimenez, Alejandro, Roman-Roman, Sergio, Rueda, Oscar M., Seoane, Joan, Serra, Violeta, Soucek, Laura, Vanhecke, Dominique, Villanueva, Alberto, Vinolo, Emilie, Bertotti, Andrea, and Trusolino, Livio

Published
2017

218. Interrogating open issues in cancer medicine with patient-derived xenografts

Author

Byrne, Annette T, Alférez, Denis G, Amant, Frédéric, Annibali, Daniela, Arribas, Joaquín, Biankin, Andrew V, Bruna, Alejandra, Budinská, Eva, Caldas, Carlos, Chang, David K, Clarke, Robert B, Clevers, Hans, Coukos, George, Dangles-Marie, Virginie, Eckhardt, S Gail, Gonzalez-Suarez, Eva, Hermans, Els, Hidalgo, Manuel, Jarzabek, Monika A, de Jong, Steven, Jonkers, Jos, Kemper, Kristel, Lanfrancone, Luisa, Mælandsmo, Gunhild Mari, Marangoni, Elisabetta, Marine, Jean-Christophe, Medico, Enzo, Norum, Jens Henrik, Palmer, Héctor G, Peeper, Daniel S, Pelicci, Pier Giuseppe, Piris-Gimenez, Alejandro, Roman-Roman, Sergio, Rueda, Oscar M, Seoane, Joan, Serra, Violeta, Soucek, Laura, Vanhecke, Dominique, Villanueva, Alberto, Vinolo, Emilie, Bertotti, Andrea, Trusolino, Livio, Byrne, Annette T, Alférez, Denis G, Amant, Frédéric, Annibali, Daniela, Arribas, Joaquín, Biankin, Andrew V, Bruna, Alejandra, Budinská, Eva, Caldas, Carlos, Chang, David K, Clarke, Robert B, Clevers, Hans, Coukos, George, Dangles-Marie, Virginie, Eckhardt, S Gail, Gonzalez-Suarez, Eva, Hermans, Els, Hidalgo, Manuel, Jarzabek, Monika A, de Jong, Steven, Jonkers, Jos, Kemper, Kristel, Lanfrancone, Luisa, Mælandsmo, Gunhild Mari, Marangoni, Elisabetta, Marine, Jean-Christophe, Medico, Enzo, Norum, Jens Henrik, Palmer, Héctor G, Peeper, Daniel S, Pelicci, Pier Giuseppe, Piris-Gimenez, Alejandro, Roman-Roman, Sergio, Rueda, Oscar M, Seoane, Joan, Serra, Violeta, Soucek, Laura, Vanhecke, Dominique, Villanueva, Alberto, Vinolo, Emilie, Bertotti, Andrea, and Trusolino, Livio

Abstract

This corrects the article DOI: 10.1038/nrc.2016.140.

Published
2017

219. Interrogating open issues in cancer precision medicine with patient-derived xenografts

Author

Byrne, Annette T, Alférez, Denis G, Amant, Frédéric, Annibali, Daniela, Arribas, Joaquín, Biankin, Andrew V, Bruna, Alejandra, Budinská, Eva, Caldas, Carlos, Chang, David K, Clarke, Robert B, Clevers, Hans, Coukos, George, Dangles-Marie, Virginie, Eckhardt, S Gail, Gonzalez-Suarez, Eva, Hermans, Els, Hidalgo, Manuel, Jarzabek, Monika A, de Jong, Steven, Jonkers, Jos, Kemper, Kristel, Lanfrancone, Luisa, Mælandsmo, Gunhild Mari, Marangoni, Elisabetta, Marine, Jean-Christophe, Medico, Enzo, Norum, Jens Henrik, Palmer, Héctor G, Peeper, Daniel S, Pelicci, Pier Giuseppe, Piris-Gimenez, Alejandro, Roman-Roman, Sergio, Rueda, Oscar M, Seoane, Joan, Serra, Violeta, Soucek, Laura, Vanhecke, Dominique, Villanueva, Alberto, Vinolo, Emilie, Bertotti, Andrea, Trusolino, Livio, Byrne, Annette T, Alférez, Denis G, Amant, Frédéric, Annibali, Daniela, Arribas, Joaquín, Biankin, Andrew V, Bruna, Alejandra, Budinská, Eva, Caldas, Carlos, Chang, David K, Clarke, Robert B, Clevers, Hans, Coukos, George, Dangles-Marie, Virginie, Eckhardt, S Gail, Gonzalez-Suarez, Eva, Hermans, Els, Hidalgo, Manuel, Jarzabek, Monika A, de Jong, Steven, Jonkers, Jos, Kemper, Kristel, Lanfrancone, Luisa, Mælandsmo, Gunhild Mari, Marangoni, Elisabetta, Marine, Jean-Christophe, Medico, Enzo, Norum, Jens Henrik, Palmer, Héctor G, Peeper, Daniel S, Pelicci, Pier Giuseppe, Piris-Gimenez, Alejandro, Roman-Roman, Sergio, Rueda, Oscar M, Seoane, Joan, Serra, Violeta, Soucek, Laura, Vanhecke, Dominique, Villanueva, Alberto, Vinolo, Emilie, Bertotti, Andrea, and Trusolino, Livio

Abstract

Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective of EurOPDX, an international initiative devoted to PDX-based research.

Published
2017

220. PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.

Author

Meehan, Terrence F, Meehan, Terrence F, Conte, Nathalie, Goldstein, Theodore, Inghirami, Giorgio, Murakami, Mark A, Brabetz, Sebastian, Gu, Zhiping, Wiser, Jeffrey A, Dunn, Patrick, Begley, Dale A, Krupke, Debra M, Bertotti, Andrea, Bruna, Alejandra, Brush, Matthew H, Byrne, Annette T, Caldas, Carlos, Christie, Amanda L, Clark, Dominic A, Dowst, Heidi, Dry, Jonathan R, Doroshow, James H, Duchamp, Olivier, Evrard, Yvonne A, Ferretti, Stephane, Frese, Kristopher K, Goodwin, Neal C, Greenawalt, Danielle, Haendel, Melissa A, Hermans, Els, Houghton, Peter J, Jonkers, Jos, Kemper, Kristel, Khor, Tin O, Lewis, Michael T, Lloyd, KC Kent, Mason, Jeremy, Medico, Enzo, Neuhauser, Steven B, Olson, James M, Peeper, Daniel S, Rueda, Oscar M, Seong, Je Kyung, Trusolino, Livio, Vinolo, Emilie, Wechsler-Reya, Robert J, Weinstock, David M, Welm, Alana, Weroha, S John, Amant, Frédéric, Pfister, Stefan M, Kool, Marcel, Parkinson, Helen, Butte, Atul J, Bult, Carol J, Meehan, Terrence F, Meehan, Terrence F, Conte, Nathalie, Goldstein, Theodore, Inghirami, Giorgio, Murakami, Mark A, Brabetz, Sebastian, Gu, Zhiping, Wiser, Jeffrey A, Dunn, Patrick, Begley, Dale A, Krupke, Debra M, Bertotti, Andrea, Bruna, Alejandra, Brush, Matthew H, Byrne, Annette T, Caldas, Carlos, Christie, Amanda L, Clark, Dominic A, Dowst, Heidi, Dry, Jonathan R, Doroshow, James H, Duchamp, Olivier, Evrard, Yvonne A, Ferretti, Stephane, Frese, Kristopher K, Goodwin, Neal C, Greenawalt, Danielle, Haendel, Melissa A, Hermans, Els, Houghton, Peter J, Jonkers, Jos, Kemper, Kristel, Khor, Tin O, Lewis, Michael T, Lloyd, KC Kent, Mason, Jeremy, Medico, Enzo, Neuhauser, Steven B, Olson, James M, Peeper, Daniel S, Rueda, Oscar M, Seong, Je Kyung, Trusolino, Livio, Vinolo, Emilie, Wechsler-Reya, Robert J, Weinstock, David M, Welm, Alana, Weroha, S John, Amant, Frédéric, Pfister, Stefan M, Kool, Marcel, Parkinson, Helen, Butte, Atul J, and Bult, Carol J

Abstract

Patient-derived tumor xenograft (PDX) mouse models have emerged as an important oncology research platform to study tumor evolution, mechanisms of drug response and resistance, and tailoring chemotherapeutic approaches for individual patients. The lack of robust standards for reporting on PDX models has hampered the ability of researchers to find relevant PDX models and associated data. Here we present the PDX models minimal information standard (PDX-MI) for reporting on the generation, quality assurance, and use of PDX models. PDX-MI defines the minimal information for describing the clinical attributes of a patient's tumor, the processes of implantation and passaging of tumors in a host mouse strain, quality assurance methods, and the use of PDX models in cancer research. Adherence to PDX-MI standards will facilitate accurate search results for oncology models and their associated data across distributed repository databases and promote reproducibility in research studies using these models. Cancer Res; 77(21); e62-66. ©2017 AACR.

Published
2017

221. Interrogating open issues in cancer precision medicine with patient-derived xenografts

Author

CMM Sectie Molecular Cancer Research, Hubrecht Institute with UMC, Cancer, Regenerative Medicine and Stem Cells, Child Health, Byrne, Annette T., Alférez, Denis G., Amant, Frédéric, Annibali, Daniela, Arribas, Joaquín, Biankin, Andrew V., Bruna, Alejandra, Budinská, Eva, Caldas, Carlos, Chang, David K., Clarke, Robert B., Clevers, Hans, Coukos, George, Dangles-Marie, Virginie, Gail Eckhardt, S., Gonzalez-Suarez, Eva, Hermans, Els, Hidalgo, Manuel, Jarzabek, Monika A., De Jong, Steven, Jonkers, Jos, Kemper, Kristel, Lanfrancone, Luisa, Mælandsmo, Gunhild Mari, Marangoni, Elisabetta, Marine, Jean Christophe, Medico, Enzo, Norum, Jens Henrik, Palmer, Héctor G., Peeper, Daniel S., Pelicci, Pier Giuseppe, Piris-Gimenez, Alejandro, Roman-Roman, Sergio, Rueda, Oscar M., Seoane, Joan, Serra, Violeta, Soucek, Laura, Vanhecke, Dominique, Villanueva, Alberto, Vinolo, Emilie, Bertotti, Andrea, Trusolino, Livio, CMM Sectie Molecular Cancer Research, Hubrecht Institute with UMC, Cancer, Regenerative Medicine and Stem Cells, Child Health, Byrne, Annette T., Alférez, Denis G., Amant, Frédéric, Annibali, Daniela, Arribas, Joaquín, Biankin, Andrew V., Bruna, Alejandra, Budinská, Eva, Caldas, Carlos, Chang, David K., Clarke, Robert B., Clevers, Hans, Coukos, George, Dangles-Marie, Virginie, Gail Eckhardt, S., Gonzalez-Suarez, Eva, Hermans, Els, Hidalgo, Manuel, Jarzabek, Monika A., De Jong, Steven, Jonkers, Jos, Kemper, Kristel, Lanfrancone, Luisa, Mælandsmo, Gunhild Mari, Marangoni, Elisabetta, Marine, Jean Christophe, Medico, Enzo, Norum, Jens Henrik, Palmer, Héctor G., Peeper, Daniel S., Pelicci, Pier Giuseppe, Piris-Gimenez, Alejandro, Roman-Roman, Sergio, Rueda, Oscar M., Seoane, Joan, Serra, Violeta, Soucek, Laura, Vanhecke, Dominique, Villanueva, Alberto, Vinolo, Emilie, Bertotti, Andrea, and Trusolino, Livio

Published
2017

222. Corrigendum

Author

Isella, Claudio, Terrasi, Andrea, Bellomo, Sara Erika, Petti, Consalvo, Galatola, Giovanni, Muratore, Andrea, Mellano, Alfredo, Senetta, Rebecca, Cassenti, Adele, Sonetto, Cristina, Inghirami, Giorgio, Trusolino, Livio, Fekete, Zsolt, De Ridder, Mark, Cassoni, Paola, Storme, Guy, Bertotti, Andrea, Medico, Enzo, Translational Radiation Oncology and Physics, Clinical sciences, and Vriendenkring VUB

Published
2016

223. Additional file 8: Figure S3. of Tankyrase inhibition impairs directional migration and invasion of lung cancer cells by affecting microtubule dynamics and polarity signals

Author

Lupo, Barbara, Vialard, Jorge, Sassi, Francesco, Angibaud, Patrick, Puliafito, Alberto, Pupo, Emanuela, Lanzetti, Letizia, Comoglio, Paolo, Bertotti, Andrea, and Trusolino, Livio

Abstract

β-catenin/TCF-dependent readouts are not substantially influenced by TNKS inactivation. (PPTX 69 kb)

Published
2016
Full Text
View/download PDF

226. Additional file 6: Figure S2. of Tankyrase inhibition impairs directional migration and invasion of lung cancer cells by affecting microtubule dynamics and polarity signals

Author

Lupo, Barbara, Vialard, Jorge, Sassi, Francesco, Angibaud, Patrick, Puliafito, Alberto, Pupo, Emanuela, Lanzetti, Letizia, Comoglio, Paolo, Bertotti, Andrea, and Trusolino, Livio

Abstract

RNA interference-mediated downregulation of TNKS phenocopies pharmacologic inhibition in impairing cell invasion and migration. (PPTX 243 kb)

Published
2016
Full Text
View/download PDF

228. Precision oncology in metastatic colorectal cancer — from biology to medicine

Author

Di Nicolantonio, Federica, Vitiello, Pietro Paolo, Marsoni, Silvia, Siena, Salvatore, Tabernero, Josep, Trusolino, Livio, Bernards, Rene, and Bardelli, Alberto

Abstract

Remarkable progress has been made in the development of biomarker-driven targeted therapies for patients with multiple cancer types, including melanoma, breast and lung tumours, although precision oncology for patients with colorectal cancer (CRC) continues to lag behind. Nonetheless, the availability of patient-derived CRC models coupled with in vitro and in vivo pharmacological and functional analyses over the past decade has finally led to advances in the field. Gene-specific alterations are not the only determinants that can successfully direct the use of targeted therapy. Indeed, successful inhibition of BRAF or KRAS in metastatic CRCs driven by activating mutations in these genes requires combinations of drugs that inhibit the mutant protein while at the same time restraining adaptive resistance via CRC-specific EGFR-mediated feedback loops. The emerging paradigm is, therefore, that the intrinsic biology of CRC cells must be considered alongside the molecular profiles of individual tumours in order to successfully personalize treatment. In this Review, we outline how preclinical studies based on patient-derived models have informed the design of practice-changing clinical trials. The integration of these experiences into a common framework will reshape the future design of biology-informed clinical trials in this field.

Published
2021
Full Text
View/download PDF

229. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

Author

Woo, Xing Yi, Giordano, Jessica, Srivastava, Anuj, Zhao, Zi-Ming, Lloyd, Michael W., de Bruijn, Roebi, Suh, Yun-Suhk, Patidar, Rajesh, Chen, Li, Scherer, Sandra, Bailey, Matthew H., Yang, Chieh-Hsiang, Cortes-Sanchez, Emilio, Xi, Yuanxin, Wang, Jing, Wickramasinghe, Jayamanna, Kossenkov, Andrew V., Rebecca, Vito W., Sun, Hua, Mashl, R. Jay, Davies, Sherri R., Jeon, Ryan, Frech, Christian, Randjelovic, Jelena, Rosains, Jacqueline, Galimi, Francesco, Bertotti, Andrea, Lafferty, Adam, O’Farrell, Alice C., Modave, Elodie, Lambrechts, Diether, ter Brugge, Petra, Serra, Violeta, Marangoni, Elisabetta, El Botty, Rania, Kim, Hyunsoo, Kim, Jong-Il, Yang, Han-Kwang, Lee, Charles, Dean, Dennis A., Davis-Dusenbery, Brandi, Evrard, Yvonne A., Doroshow, James H., Welm, Alana L., Welm, Bryan E., Lewis, Michael T., Fang, Bingliang, Roth, Jack A., Meric-Bernstam, Funda, Herlyn, Meenhard, Davies, Michael A., Ding, Li, Li, Shunqiang, Govindan, Ramaswamy, Isella, Claudio, Moscow, Jeffrey A., Trusolino, Livio, Byrne, Annette T., Jonkers, Jos, Bult, Carol J., Medico, Enzo, and Chuang, Jeffrey H.

Abstract

Patient-derived xenografts (PDXs) are resected human tumors engrafted into mice for preclinical studies and therapeutic testing. It has been proposed that the mouse host affects tumor evolution during PDX engraftment and propagation, affecting the accuracy of PDX modeling of human cancer. Here, we exhaustively analyze copy number alterations (CNAs) in 1,451 PDX and matched patient tumor (PT) samples from 509 PDX models. CNA inferences based on DNA sequencing and microarray data displayed substantially higher resolution and dynamic range than gene expression-based inferences, and they also showed strong CNA conservation from PTs through late-passage PDXs. CNA recurrence analysis of 130 colorectal and breast PT/PDX-early/PDX-late trios confirmed high-resolution CNA retention. We observed no significant enrichment of cancer-related genes in PDX-specific CNAs across models. Moreover, CNA differences between patient and PDX tumors were comparable to variations in multiregion samples within patients. Our study demonstrates the lack of systematic copy number evolution driven by the PDX mouse host.

Published
2021
Full Text
View/download PDF

230. PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models

Author

Meehan, Terrence F., primary, Conte, Nathalie, additional, Goldstein, Theodore, additional, Inghirami, Giorgio, additional, Murakami, Mark A., additional, Brabetz, Sebastian, additional, Gu, Zhiping, additional, Wiser, Jeffrey A., additional, Dunn, Patrick, additional, Begley, Dale A., additional, Krupke, Debra M., additional, Bertotti, Andrea, additional, Bruna, Alejandra, additional, Brush, Matthew H., additional, Byrne, Annette T., additional, Caldas, Carlos, additional, Christie, Amanda L., additional, Clark, Dominic A., additional, Dowst, Heidi, additional, Dry, Jonathan R., additional, Doroshow, James H., additional, Duchamp, Olivier, additional, Evrard, Yvonne A., additional, Ferretti, Stephane, additional, Frese, Kristopher K., additional, Goodwin, Neal C., additional, Greenawalt, Danielle, additional, Haendel, Melissa A., additional, Hermans, Els, additional, Houghton, Peter J., additional, Jonkers, Jos, additional, Kemper, Kristel, additional, Khor, Tin O., additional, Lewis, Michael T., additional, Lloyd, K.C. Kent, additional, Mason, Jeremy, additional, Medico, Enzo, additional, Neuhauser, Steven B., additional, Olson, James M., additional, Peeper, Daniel S., additional, Rueda, Oscar M., additional, Seong, Je Kyung, additional, Trusolino, Livio, additional, Vinolo, Emilie, additional, Wechsler-Reya, Robert J., additional, Weinstock, David M., additional, Welm, Alana, additional, Weroha, S. John, additional, Amant, Frédéric, additional, Pfister, Stefan M., additional, Kool, Marcel, additional, Parkinson, Helen, additional, Butte, Atul J., additional, and Bult, Carol J., additional

Published
2017
Full Text
View/download PDF

231. Erratum: Interrogating open issues in cancer medicine with patient-derived xenografts

Author

Byrne, Annette T., primary, Alférez, Denis G., additional, Amant, Frédéric, additional, Annibali, Daniela, additional, Arribas, Joaquín, additional, Biankin, Andrew V., additional, Bruna, Alejandra, additional, Budinská, Eva, additional, Caldas, Carlos, additional, Chang, David K., additional, Clarke, Robert B., additional, Clevers, Hans, additional, Coukos, George, additional, Dangles-Marie, Virginie, additional, Eckhardt, S. Gail, additional, Gonzalez-Suarez, Eva, additional, Hermans, Els, additional, Hidalgo, Manuel, additional, Jarzabek, Monika A., additional, de Jong, Steven, additional, Jonkers, Jos, additional, Kemper, Kristel, additional, Lanfrancone, Luisa, additional, Mælandsmo, Gunhild Mari, additional, Marangoni, Elisabetta, additional, Marine, Jean-Christophe, additional, Medico, Enzo, additional, Norum, Jens Henrik, additional, Palmer, Héctor G., additional, Peeper, Daniel S., additional, Pelicci, Pier Giuseppe, additional, Piris-Gimenez, Alejandro, additional, Roman-Roman, Sergio, additional, Rueda, Oscar M., additional, Seoane, Joan, additional, Serra, Violeta, additional, Soucek, Laura, additional, Vanhecke, Dominique, additional, Villanueva, Alberto, additional, Vinolo, Emilie, additional, Bertotti, Andrea, additional, and Trusolino, Livio, additional

Published
2017
Full Text
View/download PDF

233. Abstract CT005: Final results of the HERACLES trial in HER2-amplified colorectal cancer

Author

Siena, Salvatore, primary, Sartore-Bianchi, Andrea, additional, Trusolino, Livio, additional, Martino, Cosimo, additional, Bencardino, Katia, additional, Lonardi, Sara, additional, Zagonel, Vittorina, additional, Leone, Francesco, additional, Martinelli, Erika, additional, Ciardiello, Fortunato, additional, Racca, Patrizia, additional, Amatu, Alessio, additional, Palmeri, Laura, additional, Valtorta, Emanuele, additional, Ghezzi, Silvia, additional, Vanzulli, Angelo, additional, Regge, Daniele, additional, Veronese, Silvio, additional, Bardelli, Alberto, additional, and Marsoni, Silvia, additional

Published
2017
Full Text
View/download PDF

234. Abstract 1742: Cancer cell-selective transcriptome analysis reveals new colorectal cancer molecular subtypes with improved biological resolution and superior predictive and prognostic performance

Author

Isella, Claudio, primary, Bellomo, Sara E., additional, Brundu, Francesco, additional, Galimi, Francesco, additional, Ficarra, Elisa, additional, Marchionni, Luigi, additional, Trusolino, Livio, additional, Bertotti, Andrea, additional, and Medico, Enzo, additional

Published
2017
Full Text
View/download PDF

235. RET rearrangements define a new and rare molecular subtype of metastatic colorectal cancer (mCRC)

Author

Pietrantonio, Filippo, primary, Schrock, Alexa, additional, Lee, Jeeyun, additional, Drilon, Alexander, additional, Christiansen, Jason, additional, Chiu, Vi, additional, Fucà, Giovanni, additional, Morano, Federica, additional, Rossini, Daniele, additional, Kim Seung, Tae, additional, Milione, Massimo, additional, Patel, Rupal, additional, Miller, Vincent, additional, Prisciandaro, Michele, additional, Di Bartolomeo, Maria, additional, Ross, Jeffrey, additional, Bertotti, Andrea, additional, Ali, Siraj, additional, Trusolino, Livio, additional, Falcone, Alfredo, additional, de Braud, Filippo, additional, and Cremolini, Chiara, additional

Published
2017
Full Text
View/download PDF

236. Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer

Author

Isella, Claudio, primary, Brundu, Francesco, additional, Bellomo, Sara E., additional, Galimi, Francesco, additional, Zanella, Eugenia, additional, Porporato, Roberta, additional, Petti, Consalvo, additional, Fiori, Alessandro, additional, Orzan, Francesca, additional, Senetta, Rebecca, additional, Boccaccio, Carla, additional, Ficarra, Elisa, additional, Marchionni, Luigi, additional, Trusolino, Livio, additional, Medico, Enzo, additional, and Bertotti, Andrea, additional

Published
2017
Full Text
View/download PDF

237. Interrogating open issues in cancer precision medicine with patient-derived xenografts

Author

Byrne, Annette T., primary, Alférez, Denis G., additional, Amant, Frédéric, additional, Annibali, Daniela, additional, Arribas, Joaquín, additional, Biankin, Andrew V., additional, Bruna, Alejandra, additional, Budinská, Eva, additional, Caldas, Carlos, additional, Chang, David K., additional, Clarke, Robert B., additional, Clevers, Hans, additional, Coukos, George, additional, Dangles-Marie, Virginie, additional, Eckhardt, S. Gail, additional, Gonzalez-Suarez, Eva, additional, Hermans, Els, additional, Hidalgo, Manuel, additional, Jarzabek, Monika A., additional, de Jong, Steven, additional, Jonkers, Jos, additional, Kemper, Kristel, additional, Lanfrancone, Luisa, additional, Mælandsmo, Gunhild Mari, additional, Marangoni, Elisabetta, additional, Marine, Jean-Christophe, additional, Medico, Enzo, additional, Norum, Jens Henrik, additional, Palmer, Héctor G., additional, Peeper, Daniel S., additional, Pelicci, Pier Giuseppe, additional, Piris-Gimenez, Alejandro, additional, Roman-Roman, Sergio, additional, Rueda, Oscar M., additional, Seoane, Joan, additional, Serra, Violeta, additional, Soucek, Laura, additional, Vanhecke, Dominique, additional, Villanueva, Alberto, additional, Vinolo, Emilie, additional, Bertotti, Andrea, additional, and Trusolino, Livio, additional

Published
2017
Full Text
View/download PDF

239. Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga

Author

Catalano, Irene, Grassi, Elena, Bertotti, Andrea, and Trusolino, Livio

Abstract

Immunotherapy with immune checkpoint inhibitors is an approved treatment option for a subpopulation of patients with colorectal cancers that display microsatellite instability. However, not all individuals within this subgroup respond to immunotherapy, and molecular biomarkers for effective patient stratification are still lacking. In this opinion article, we provide an overview of the different biological parameters that contribute to rendering colorectal cancers with microsatellite instability potentially sensitive to immunotherapy. We critically discuss the reasons why such parameters have limited predictive value and the implications therein. We also consider that a more informed knowledge of response determinants in this tumor subtype could help understand the mechanisms of immunotherapy resistance in microsatellite stable tumors. We conclude that the dynamic nature of the interactions between cancer and immune cells complicates conventional biomarker development and argue that a new generation of adaptive metrics, borrowed from evolutionary genetics, may improve the effectiveness and reliability of clinical decision making.

Published
2019
Full Text
View/download PDF

240. Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification.

Author

Cortese, Marco, Torchiaro, Erica, D’Andrea, Alice, Petti, Consalvo, Invrea, Federica, Franco, Letizia, Donini, Chiara, Leuci, Valeria, Leto, Simonetta Maria, Vurchio, Valentina, Cottino, Francesca, Isella, Claudio, Arena, Sabrina, Vigna, Elisa, Bertotti, Andrea, Trusolino, Livio, Sangiolo, Dario, and Medico, Enzo

Abstract

HER2 amplification occurs in about 5% of colorectal cancer (CRC) cases and is associated only partially with clinical response to combined HER2/EGFR targeted treatment. An alternative approach based on adoptive cell therapy (ACT) using T-cells engineered with anti-HER2 chimeric antigen receptor (CAR) proved to be toxic due to "on-target off-tumor" activity. Here we describe a combinatorial strategy to safely target HER2 amplification and CEA expression in CRC using a synNotch-CAR based artificial regulatory network. The natural killer cell line NK-92 was engineered with an anti-HER2 synNotch receptor driving the expression of a CAR against CEA only when engaged. After being transduced and sorted for HER2-driven CAR expression, cells were cloned. The clone with optimal performances in terms of specificity and amplitude of CAR induction demonstrated significant activity in vitroand in vivospecifically against HER2amp/CEA+ CRC models, with no effects on cells with physiological HER2 levels. The HER2-synNotch/CEA-CAR-NK system provides an innovative, scalable and safe off-the shelf cell therapy approach with potential against HER2amp CRC resistant or partially responsive to HER2/EGFR blockade.

Published
2024
Full Text
View/download PDF

241. Author Correction: Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer

Author

Malla, Sudhir B., Byrne, Ryan M., Lafarge, Maxime W., Corry, Shania M., Fisher, Natalie C., Tsantoulis, Petros K., Mills, Megan L., Ridgway, Rachel A., Lannagan, Tamsin R. M., Najumudeen, Arafath K., Gilroy, Kathryn L., Amirkhah, Raheleh, Maguire, Sarah L., Mulholland, Eoghan J., Belnoue-Davis, Hayley L., Grassi, Elena, Viviani, Marco, Rogan, Emily, Redmond, Keara L., Sakhnevych, Svetlana, McCooey, Aoife J., Bull, Courtney, Hoey, Emily, Sinevici, Nicoleta, Hall, Holly, Ahmaderaghi, Baharak, Domingo, Enric, Blake, Andrew, Richman, Susan D., Isella, Claudio, Miller, Crispin, Bertotti, Andrea, Trusolino, Livio, Loughrey, Maurice B., Kerr, Emma M., Tejpar, Sabine, Maughan, Timothy S., Lawler, Mark, Campbell, Andrew D., Leedham, Simon J., Koelzer, Viktor H., Sansom, Owen J., and Dunne, Philip D.

Published
2024
Full Text
View/download PDF

242. Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer

Author

Picco, Gabriele, primary, Petti, Consalvo, additional, Sassi, Francesco, additional, Grillone, Katia, additional, Migliardi, Giorgia, additional, Rossi, Teresa, additional, Isella, Claudio, additional, Di Nicolantonio, Federica, additional, Sarotto, Ivana, additional, Sapino, Anna, additional, Bardelli, Alberto, additional, Trusolino, Livio, additional, Bertotti, Andrea, additional, and Medico, Enzo, additional

Published
2016
Full Text
View/download PDF

243. A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors

Author

Gelfo, Valerio, primary, Rodia, Maria Teresa, additional, Pucci, Michela, additional, Dall’Ora, Massimiliano, additional, Santi, Spartaco, additional, Solmi, Rossella, additional, Roth, Lee, additional, Lindzen, Moshit, additional, Bonafè, Massimiliano, additional, Bertotti, Andrea, additional, Caramelli, Elisabetta, additional, Lollini, Pier-Luigi, additional, Trusolino, Livio, additional, Yarden, Yosef, additional, D’Uva, Gabriele, additional, and Lauriola, Mattia, additional

Published
2016
Full Text
View/download PDF

244. Erratum: Corrigendum: Stromal contribution to the colorectal cancer transcriptome

Author

Isella, Claudio, primary, Terrasi, Andrea, additional, Bellomo, Sara Erika, additional, Petti, Consalvo, additional, Galatola, Giovanni, additional, Muratore, Andrea, additional, Mellano, Alfredo, additional, Senetta, Rebecca, additional, Cassenti, Adele, additional, Sonetto, Cristina, additional, Inghirami, Giorgio, additional, Trusolino, Livio, additional, Fekete, Zsolt, additional, De Ridder, Mark, additional, Cassoni, Paola, additional, Storme, Guy, additional, Bertotti, Andrea, additional, and Medico, Enzo, additional

Published
2016
Full Text
View/download PDF

246. Abstract B17: Xenospheres: a comprehensive patient-derived in vitro model to study response and resistance to targeted therapies in metastatic colorectal cancer

Author

Luraghi, Paolo, primary, Bigatto, Viola, additional, Reato, Gigliola, additional, Cipriano, Elia, additional, Sassi, Francesco, additional, Isella, Claudio, additional, Bertotti, Andrea, additional, Trusolino, Livio, additional, Comoglio, Paolo Maria, additional, and Boccaccio, Carla, additional

Published
2016
Full Text
View/download PDF

249. Abstract CT082: Pertuzumab and trastuzumab-emtansine in HER2-positive colorectal cancer: the HERACLES B trial

Author

Trusolino, Livio, primary, Bertotti, Andrea, additional, Lonardi, Sara, additional, Sartore-Bianchi, Andrea, additional, Martino, Cosimo, additional, Cottino, Francesca, additional, Vurchio, Valentina, additional, Valtorta, Emanuele, additional, Lauricella, Calogero, additional, Regge, Daniele, additional, Vanzulli, Angelo, additional, Zagonel, Vittorina, additional, Leone, Francesco, additional, Racca, Patrizia, additional, Ciardiello, Fortunato, additional, Ardizzoni, Andrea, additional, Marsoni, Silvia, additional, and Siena, Salvatore, additional

Published
2016
Full Text
View/download PDF

250. Abstract LB-354: Investigating potential molecular biomarkers for cetuximab response in metastatic colorectal cancer tissue using reverse phase protein array

Author

Monsefi, Naser, primary, O’Byrne, Robert, additional, Carberry, Steven, additional, Zanella, Eugenia R., additional, Barat, Ana, additional, Cremona, Mattia, additional, Morgan, Clare, additional, Hennessy, Bryan T., additional, Bertotti, Andrea, additional, Trusolino, Livio, additional, and Prehn, Jochen H.M., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results